Literature DB >> 26926076

IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma.

Zewei Wang1, Le Xu2, Yuan Chang3, Lin Zhou3, Hangcheng Fu1, Weijuan Zhang4, Yuanfeng Yang5, Jiejie Xu6.   

Abstract

The aim of this study was to evaluate the potential prognostic significance of interleukin-33 (IL-33) in patients with clear-cell renal cell carcinoma (ccRCC) after surgical resection. In this retrospective research, we enrolled 203 patients with ccRCC undergoing nephrectomy between 2003 and 2004 in a single institution. We recorded clinicopathologic features, overall survival (OS), and recurrence-free survival (RFS) and assessed IL-33 expression by immunohistochemical staining. On such bases, the correlations between IL-33 expression and clinicopathologic features and prognosis were evaluated. A high expression of IL-33 was significantly associated with advanced TNM stage and Fuhrman grade (p = 0.017 and p < 0.001, respectively) in patients with ccRCC. Moreover, multivariate analysis identified IL-33 as an independent prognostic factor of OS for patients with ccRCC after surgery (hazard ratio = 2.050; 95 % CI 1.223-3.447; p = 0.006). The incorporation of IL-33 into the TNM stage and Fuhrman grade might help to refine individual risk stratification. The IL-33 expression may serve as an independent negative predictor of survival for patients with ccRCC after surgery.

Entities:  

Keywords:  Clear-cell renal cell carcinoma; Interleukin-33; Overall survival; Prognostic biomarker

Mesh:

Substances:

Year:  2016        PMID: 26926076     DOI: 10.1007/s13277-016-4879-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  26 in total

Review 1.  Nuclear factor-kappaB in cancer development and progression.

Authors:  Michael Karin
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

Review 2.  Basic research in kidney cancer.

Authors:  Egbert Oosterwijk; W Kimryn Rathmell; Kerstin Junker; A Rose Brannon; Frédéric Pouliot; David S Finley; Peter F A Mulders; Ziya Kirkali; Hirotsugo Uemura; Arie Belldegrun
Journal:  Eur Urol       Date:  2011-07-05       Impact factor: 20.096

Review 3.  Prognostic factors and predictive models in renal cell carcinoma: a contemporary review.

Authors:  Maxine Sun; Shahrokh F Shariat; Christopher Cheng; Vincenzo Ficarra; Masaru Murai; Stéphane Oudard; Allan J Pantuck; Richard Zigeuner; Pierre I Karakiewicz
Journal:  Eur Urol       Date:  2011-06-30       Impact factor: 20.096

4.  Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production.

Authors:  Yeon-Sook Choi; Hyun-Jung Choi; Jeong-Ki Min; Bo-Jeong Pyun; Yong-Sun Maeng; Hongryeol Park; Jihye Kim; Young-Myeong Kim; Young-Guen Kwon
Journal:  Blood       Date:  2009-08-06       Impact factor: 22.113

5.  IL-33 Promotes Gastric Cancer Cell Invasion and Migration Via ST2-ERK1/2 Pathway.

Authors:  Xi-Xiang Yu; Zhe Hu; Xian Shen; Li-Yang Dong; Wei-Zhong Zhou; Wen-Hao Hu
Journal:  Dig Dis Sci       Date:  2015-02-06       Impact factor: 3.199

6.  High Serum Levels of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma.

Authors:  Dominik Bergis; Valentin Kassis; Annika Ranglack; Verena Koeberle; Albrecht Piiper; Bernd Kronenberger; Stefan Zeuzem; Oliver Waidmann; Heinfried H Radeke
Journal:  Transl Oncol       Date:  2013-06-01       Impact factor: 4.243

7.  IL-33 attenuates EAE by suppressing IL-17 and IFN-γ production and inducing alternatively activated macrophages.

Authors:  Hui-Rong Jiang; Marija Milovanović; Debbie Allan; Wanda Niedbala; Anne-Galle Besnard; Sandra Y Fukada; Jose C Alves-Filho; Dieudonnée Togbe; Carl S Goodyear; Christopher Linington; Damo Xu; Miodrag L Lukic; Foo Y Liew
Journal:  Eur J Immunol       Date:  2012-06-12       Impact factor: 5.532

8.  Role of IL-33 in inflammation and disease.

Authors:  Ashley M Miller
Journal:  J Inflamm (Lond)       Date:  2011-08-26       Impact factor: 4.981

9.  IL-33/ST2 axis in innate and acquired immunity to tumors.

Authors:  Ivan P Jovanovic; Nada N Pejnovic; Gordana D Radosavljevic; Nebojsa N Arsenijevic; Miodrag L Lukic
Journal:  Oncoimmunology       Date:  2012-03-01       Impact factor: 8.110

10.  Role of IL-33 and its receptor in T cell-mediated autoimmune diseases.

Authors:  Qing Zhao; Guangjie Chen
Journal:  Biomed Res Int       Date:  2014-06-16       Impact factor: 3.411

View more
  6 in total

Review 1.  Emerging Roles of IL-33/ST2 Axis in Renal Diseases.

Authors:  Wei-Yu Chen; Lung-Chih Li; Jenq-Lin Yang
Journal:  Int J Mol Sci       Date:  2017-04-07       Impact factor: 5.923

2.  Cellular and clinicopathological features of the IL-33/ST2 axis in human esophageal squamous cell carcinomas.

Authors:  Guanglin Cui; Jingli Ren; Gang Xu; Zhenfeng Li; Wei Zheng; Aping Yuan
Journal:  Cancer Cell Int       Date:  2018-12-11       Impact factor: 5.722

3.  Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy.

Authors:  Markus Kieler; Matthias Unseld; Johann Wojta; Alexandra Kaider; Daniela Bianconi; Svitlana Demyanets; Gerald W Prager
Journal:  Med Oncol       Date:  2018-11-13       Impact factor: 3.064

Review 4.  Contribution of IL-33 to the Pathogenesis of Colorectal Cancer.

Authors:  Guanglin Cui; Aping Yuan; Zhigang Pang; Wei Zheng; Zhenfeng Li; Rasmus Goll
Journal:  Front Oncol       Date:  2018-11-28       Impact factor: 6.244

Review 5.  The Pro-tumorigenic IL-33 Involved in Antitumor Immunity: A Yin and Yang Cytokine.

Authors:  Jean-Jacques Fournié; Mary Poupot
Journal:  Front Immunol       Date:  2018-10-26       Impact factor: 7.561

Review 6.  The Pleiotropic Immunomodulatory Functions of IL-33 and Its Implications in Tumor Immunity.

Authors:  Claudia Afferni; Carla Buccione; Sara Andreone; Maria Rosaria Galdiero; Gilda Varricchi; Gianni Marone; Fabrizio Mattei; Giovanna Schiavoni
Journal:  Front Immunol       Date:  2018-11-13       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.